Reply: Niacin therapy improves outcome and normalizes metabolic abnormalities in an NAXD-deficient patient
Brain
.
2022 Jun 3;145(5):e41-e42.
doi: 10.1093/brain/awac066.
Authors
Nicole J Van Bergen
1
2
,
Adhish S Walvekar
3
,
Carole L Linster
3
,
John Christodoulou
1
2
3
4
Affiliations
1
Brain and Mitochondrial Research Group, Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Australia.
2
Department of Paediatrics, University of Melbourne, Melbourne, Australia.
3
Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux L-4367, Luxembourg.
4
Victorian Clinical Genetics Services, Royal Children's Hospital, Melbourne, VIC, Australia.
PMID:
35254397
DOI:
10.1093/brain/awac066
No abstract available
Publication types
Editorial
Comment
MeSH terms
Cholesterol, HDL
Humans
Niacin* / therapeutic use
Substances
Cholesterol, HDL
Niacin